Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease.
OBJECTIVE
In preterm infants, chronic lung disease (CLD) is associated with an increased risk for cerebral palsy (CP). However, systemic postnatal corticosteroid therapy to prevent or treat CLD, although effective in improving lung function, may cause CP. The objective of this study was to determine the effect of systemic postnatal corticosteroid treatment on death and CP and to assess any modification of effect arising from risk for CLD.


METHODS
Randomized, controlled trials of postnatal corticosteroid therapy for prevention or treatment of CLD in preterm infants that reported rates of both mortality and CP were reviewed and their data were synthesized. Twenty studies with data on 1721 randomized infants met eligibility criteria. The relationship between the corticosteroid effect on the combined outcome, death or CP, and the risk for CLD in control groups was analyzed by weighted meta-regression.


RESULTS
Among all infants who were randomized, a significantly higher rate of CP after corticosteroid treatment (typical risk difference [RD]: 0.05; 95% confidence interval [CI]: 0.02, 0.08) was partly offset by a nonsignificant reduction in mortality (typical RD: -0.02; 95% CI: -0.06 to 0.02). Consequently, there was no significant effect of corticosteroid treatment on the combined rate of mortality or CP (typical RD: 0.03; 95% CI: -0.01 to 0.08). However, on meta-regression, there was a significant negative relationship between the treatment effect on death or CP and the risk for CLD in control groups. With risks for CLD below 35%, corticosteroid treatment significantly increased the chance of death or CP, whereas with risks for CLD exceeding 65%, it reduced this chance.


CONCLUSIONS
The effect of postnatal corticosteroids on the combined outcome of death or CP varies with the level of risk for CLD.
Doyle
Lex W
LW
Division of Paediatrics, Royal Women's Hospital, 132 Grattan St, Carlton 3053, Australia. lwd@unimelb.edu.au
Halliday
Henry L
HL
Ehrenkranz
Richard A
RA
Davis
Peter G
PG
Sinclair
John C
JC
D000305:Adrenal Cortex Hormones / Q000009:adverse effects* / Q000627:therapeutic use; D002547:Cerebral Palsy / Q000139:chemically induced*; D002908:Chronic Disease; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000401:mortality*; D008171:Lung Diseases / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D012306:Risk
D000305:Adrenal Cortex Hormones